207 related articles for article (PubMed ID: 29973205)
1. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
3. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
Woods DC; Alvarez C; Johnson AL
Gynecol Oncol; 2008 Mar; 108(3):632-40. PubMed ID: 18191995
[TBL] [Abstract][Full Text] [Related]
7. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
Wahl H; Tan L; Griffith K; Choi M; Liu JR
Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
[TBL] [Abstract][Full Text] [Related]
8. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
9. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
10. Identification of nuclear export inhibitors with potent anticancer activity in vivo.
Mutka SC; Yang WQ; Dong SD; Ward SL; Craig DA; Timmermans PB; Murli S
Cancer Res; 2009 Jan; 69(2):510-7. PubMed ID: 19147564
[TBL] [Abstract][Full Text] [Related]
11. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
12. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
[TBL] [Abstract][Full Text] [Related]
13. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Bräutigam K; Biernath-Wüpping J; Bauerschlag DO; von Kaisenberg CS; Jonat W; Maass N; Arnold N; Meinhold-Heerlein I
J Cancer Res Clin Oncol; 2011 May; 137(5):875-86. PubMed ID: 20878528
[TBL] [Abstract][Full Text] [Related]
19. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy.
Gao W; Lu C; Chen L; Keohavong P
J Thorac Oncol; 2015 May; 10(5):815-825. PubMed ID: 25629636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]